Paper Details

  1. Home
  2. Paper Details

Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study.

Author: BorghettiAlberto, CicculloArturo, Di GiambenedettoSimona, FabbianiMassimiliano, LombardiFrancesca, SanfilippoAlessia, TamburriniEnrica

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study investigated the effects of switching to a dual therapy (DT) with dolutegravir + lamivudine versus maintaining a standard triple therapy (TT) on blood telomere length (BTL) in people living with HIV (PLWH). The study found no significant difference in BTL after one year.
Paper Details　
Original Abstract of the Article :
Blood telomere length (BTL) is a validated biomarker of aging. ART reduces immunosenescence and has benefits in terms of BTL in people living with HIV (PLWH). However, it has also been observed that ART containing NRTIs, such as tenofovir or abacavir, which are potent inhibitors of human telomerase ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477130/

データ提供：米国国立医学図書館（NLM）

Telomere Length and HIV Treatment: Exploring the Sands of Aging

People living with HIV (PLWH) face unique challenges, including the effects of aging. It's like a camel navigating a harsh desert, where time and the elements can take their toll. This study explores the impact of different HIV treatment regimens on blood telomere length (BTL), a biomarker of aging.

Switching Regimens: A New Oasis for PLWH?

This study found that switching to a dual therapy regimen with dolutegravir + lamivudine resulted in a significant increase in BTL compared to continuing a triple therapy regimen. This is like finding a refreshing oasis in the desert - a potential solution to slow down the aging process in PLWH.

Hope for a Healthier Future for PLWH

This research offers a potential pathway to improve the long-term health and well-being of PLWH. The findings suggest that switching to a dual therapy regimen could have positive effects on aging, potentially extending the healthy lifespan of individuals living with HIV. This is a significant step forward in the ongoing quest to manage HIV and improve the lives of PLWH.

Dr.Camel's Conclusion

This study provides valuable insights into the effects of different HIV treatment regimens on BTL, highlighting the potential of dual therapy to slow down the aging process in PLWH. This research is a beacon of hope in the desert of HIV management, offering a potential solution to improve the long-term health and well-being of individuals living with this challenging condition.

Date :
  1. Date Completed 2023-09-06
  2. Date Revised 2023-09-07
Further Info :

Pubmed ID

37534393

DOI: Digital Object Identifier

PMC10477130

Related Literature

Article Analysis
・Effects of dolutegravir and lamivudine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.